Intra-articular Polyacrylamide Hydrogel in Knee Osteoarthritis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

144 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-29

Study Completion Date

2020-12-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this double-blinded controlled study is to assess clinical efficacy and safety of intra-articular HBISA Endoprosthesis of Synovial Fluid (polyacrylamide hydrogel) in comparison with placebo (0.9% sodium chloride solution) in Kellgren Lawrence radiological grade II-III knee osteoarthritis

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intra-articular Polyacrylamide Hydrogel in Gonarthrosis

NCT06429319

Osteoarthritis

COMPLETED NA

Intra-articular Polyacrylamide Hydrogel in the Treatment of Knee Osteoarthritis

NCT06523491

Osteoarthritis, Knee

COMPLETED

Intra-articular PVA Hydrogel in Knee Osteoarthritis

NCT04693104

Knee Osteoarthritis

COMPLETED NA

Cellular Matrix Device for the Treatment of Mild to Moderate Knee Osteoarthritis

NCT03328728

Knee Osteoarthritis

UNKNOWN NA

Pilot, Prospective, Comparative Multicentric Study Evaluating the Effects on the Arthrosis Biomarkers, the Clinical Effectiveness, the Tolerance of an Intra-articular Injection of Hyaluronic Acid KARTILAGE CROSS Versus Placebo in Patients Suffering From Knee Osteoarthritis

NCT02951585

Knee Osteoarthritis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Polyacrylamide hydrogel (hereinafter - PAAG) is intended for a symptomatic effect leading to decrease of joint pain intensity and improvement of functional joint characteristics. Therefore PAAG is regarded as symptom-modifying therapy for joint osteoarthritis (hereinafter - OA). The aim of this study was to estimate efficacy and safety of intra-articular injections of PAAG in comparison with saline solution. Men and women above 50 years with verified knee osteoarthritis in accordance with the American College of Rheumatology (ACR) criteria were randomly assigned to one of 2 groups (PAAG or saline solution). Each patient received to the target knee joint one injection of 4.0 ml either PAAG or placebo with one-week interval. Course - 2 injections. To avoid the joint overfilling with the dense, slowly resorbing material in patients with a good clinical result, the course of injections was to be stopped. Primary and secondary efficacy endpoints, and safety parameters were assessed at weeks 6, 13 and 25 visits .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

multicenter double-blind randomized comparative placebo-controlled

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

A patient, study investigator and Sponsor representative (monitoring specialist) will not know to which group a patient is included. to preserve blinding of any patient and study team, an independent unblended physician is to be engaged, he/she will receive the product per randomization code and perform the procedure of intra-articular injection of the study MD and placebo.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NOLTREX™, OA grade II-III

72 patients with gonarthrosis grade II-III were randomised to receive PAHG

Group Type EXPERIMENTAL

hydrous biopolymer with silver ions "Argiform"

Intervention Type DEVICE

2 once-weekly intra-articular injections of NOLTREX™ 4.0 ml

Placebo,OA grade II-III

72 patients with gonarthrosis grade II-III were randomised to receive saline solution

Group Type PLACEBO_COMPARATOR

saline solution

Intervention Type DEVICE

2 once-weekly intra-articular injections of saline solution 4 ml

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hydrous biopolymer with silver ions "Argiform"

2 once-weekly intra-articular injections of NOLTREX™ 4.0 ml

Intervention Type DEVICE

saline solution

2 once-weekly intra-articular injections of saline solution 4 ml

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

polyacrylamide hydrogel with silver ions Synovial fluid endoprosthesis NOLTREX™

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women above 50 years;
* Verified knee osteoarthritis in accordance with the ACR (knee pain combined with one of the following signs: age above 50 years, knee crepitus or morning joint stiffness lasting for less than 30 minutes combined with radiologic signs of knee osteoarthritis);
* Kellgren Lawrence radiological grade II-III knee osteoarthritis with the predominant involvement of the medial tibiofemoral region of the knee joint;
* Joint space width (JSW) of the target knee joint at least 2.5 mm.

Exclusion Criteria

1. History of any injury or surgical intervention on the target knee joint (except for diagnostic arthroscopy made not longer than 60 days at the study entry);
2. Severe degenerative changes in the target knee joint determined as the joint space narrowing less than 2 mm;
3. Varus or valgus deformation of the target knee joint;
4. Instability of the target knee joint;
5. Active inflammation of the target knee joint (edema, hyperemia, present effusion) at the study entry;
6. Microcrystalline arthropathies;
7. Systemic inflammatory disease (rheumatoid arthritis, systemic lupus erythematosus, etc.);
8. Seronegative spondyloarthritis and reactive arthritis;
9. Inflammatory diseases of the skin and soft tissues in the proposed injection site for the test MD or placebo in the target joint;
10. History of venous thrombosis and thromboembolia;
11. Coagulogram abnormalities (APTT, prothrombin time, prothrombin index, fibrinogen);
12. Inflammatory changes in the complete blood count (leukocytosis, increase of erythrocyte sedimentation rate \[ESR\]);
13. Platelet count abnormality (in accordance with the reference ranges of the local laboratory;
14. Increase of rheumatoid factor level;
15. Increase of uric acid level \> 360 μmol/l;
16. Diabetes mellitus;
17. Hemophilia and other hemorrhagic diatheses, as well administration of anticoagulants and disaggregants;
18. Positive results of HIV, HBs-Ag, anti-HCV, RW tests;
19. Intra-articular injection to the target knee joint:

* Noltrex - within 24 months prior patient's inclusion to the study;
* hyaluronates - within 6 months prior patient's inclusion to the study;
* glucocorticosteroids - within 1 month prior the study inclusion;
* non-steroidal anti-inflammatory drugs (NSAID) - within 3 weeks prior patient's inclusion to the study.
20. Oral administration of non-steroidal anti-inflammatory drugs (NSAID) within 2 weeks prior the study inclusion;
21. Necessity of systemic glucocorticosteroids in any dosage form;
22. Paracetamol administration within 48 hours prior the study inclusion;
23. Pregnancy and lactation;
24. Hypersensitivity to components of the test MD or placebo;
25. Severe liver disorder determined as the increase of one of the values: ALT, AST, ALP, total bilirubin, GGTP more than 3 times the upper limit of normal;
26. Renal diseases with the glomerular filtration rate estimated per Cockraft-Gault formula less than 60 ml/min/1.73 m2 (III-V stage chronic renal disease \[CRD\]);
27. Clinically manifest hip osteoarthritis;
28. History of knee and coxofemoral endoprosthesis;
29. Acute infectious diseases or infectious aggravations of chronic diseases (respiratory infections) within one month prior the study inclusion;
30. Severe decompensated chronic or acute diseases and other conditions which, by the opinion of the study physician, may preclude the patient's participation in the study or affect the study results.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No